8-K: Candel Therapeutics Reports Q3 2025 Results, Advances Pipeline

Candel Therapeutics announced its third quarter 2025 financial results, highlighted by progress in its CAN-2409 and CAN-3110 clinical programs and a new $130 million term loan facility.

Summary

• Third quarter 2025 financial results were announced, with a net loss of $11.3 million compared to $10.6 million in Q3 2024.
• New subgroup analyses from the phase 3 clinical trial of CAN-2409 in localized prostate cancer were presented at ASTRO 2025, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality.
• Plans are in place to initiate a pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026.
• Encouraging updated survival data for patients enrolled in the phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent high-grade glioma (rHGG) were announced.
• A manuscript reporting the tissue response to CAN-3110 was published in the scientific journal Science Translational Medicine.
• A Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer is planned for submission in Q4 2026.
• A $130 million term loan facility was entered into with Trinity Capital Inc., with $50 million drawn down at closing and access to up to an additional $80 million.
• Cash and cash equivalents were $87.0 million as of September 30, 2025, which, combined with the upfront debt proceeds, is expected to fund operations into Q1 2027.
• The CAN-2409 pancreatic cancer program will be paused unless funded through external, non-dilutive funding.
• Dr. Carl H. June and Dr. Bali Pulendran were appointed to the Research Advisory Board.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for both lead candidates, particularly the statistically significant DFS improvement for CAN-2409 in prostate cancer and encouraging survival data for CAN-3110 in rHGG. The securing of a substantial non-dilutive debt facility significantly strengthens the company's financial position and extends its cash runway, enabling the advancement of key programs. While operating expenses and net loss increased, this is typical for a clinical-stage biotech with active trials, and the funding addresses immediate capital needs. The pausing of the PDAC program is a strategic prioritization, not necessarily a negative for the overall pipeline.

Positives

• CAN-2409 phase 3 clinical trial in localized prostate cancer demonstrated statistically significant improvement in prostate cancer-specific DFS (Hazard Ratio (HR) 0.62; p=0.0046), with effects observed across both moderate hypo-fractionated and conventional external beam radiation therapy (EBRT).
• CAN-2409 administration was safe across radiation therapy modalities, showing similar tolerability profiles with Grade 3 treatment related adverse events comparable to placebo.
• The U.S. Food and Drug Administration (FDA) previously granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to CAN-2409 for the treatment of prostate cancer.
• The FDA previously granted Fast Track Designation to CAN-2409 for the treatment of NSCLC.
• The FDA previously granted Fast Track Designation and Orphan Drug Designation to CAN-2409 for the treatment of pancreatic ductal adenocarcinoma (PDAC), and the European Medicines Agency granted Orphan Designation for CAN-2409 for pancreatic cancer.
• Encouraging updated survival data for CAN-3110 in rHGG showed median overall survival (mOS) of 11.8 months (Arm A) and 12.0 months (Arm B) after a single injection, with two patients still alive after prolonged follow-up (59.2 and 42.4 months).
• CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA in recurrent high-grade glioma.
• Secured a strategic, non-dilutive $130 million term loan facility with Trinity Capital Inc., with $50 million drawn at closing.
• Cash and cash equivalents of $87.0 million as of September 30, 2025, combined with the upfront debt proceeds, strengthens the financial position to fund operations into Q1 2027.
• Strengthened the Research Advisory Board with the appointments of internationally recognized experts Dr. Carl H. June and Dr. Bali Pulendran.

Negatives

• Net loss for the third quarter of 2025 increased to $11.3 million compared to $10.6 million for the third quarter of 2024.
• Research and development expenses increased to $8.5 million for Q3 2025 from $5.4 million for Q3 2024, primarily due to increased manufacturing, regulatory, and employee-related costs.
• General and administrative expenses increased to $4.7 million for Q3 2025 from $3.3 million for Q3 2024, primarily due to increased commercial readiness costs and employee-related expenses.
• Cash and cash equivalents decreased to $87.0 million as of September 30, 2025, from $102.7 million as of December 31, 2024.
• The CAN-2409 pancreatic cancer program will be paused unless funded through external, non-dilutive funding, indicating a reprioritization of resources away from this indication.

Risks

• The timing and advancement of current and future development programs, including the timing and availability of additional data and key data readout milestones, are subject to uncertainties.
• Expectations regarding the therapeutic benefit of the Company's platforms, including the ability to improve overall survival and/or disease-free survival, may not be realized.
• Final data from preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials.
• The ability to efficiently discover and develop product candidates is crucial for success.
• The ability to obtain and maintain regulatory approval of product candidates is a significant hurdle.
• Maintaining intellectual property rights is essential for protecting the Company's assets.
• The implementation of the Company's business model, including strategic plans for its business and product candidates, carries inherent risks.
• The impact of existing and any future indebtedness on the ability to operate the business is a financial risk.
• The ability to access any future tranches under the debt facility and to comply with all obligations thereunder is not guaranteed.

Future Outlook

The company anticipates submitting a Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer in Q4 2026. A pivotal phase 3 clinical trial of CAN-2409 in NSCLC is planned for initiation in Q2 2026. Updated data from the phase 2a NSCLC study is expected in Q1 2026, and extended follow-up data for the prostate cancer phase 3 study is expected in Q2 2026. Immunologic biomarker data from a mechanistic prostate cancer study is anticipated in Q3 2026, and mature overall survival data for CAN-3110 Arm C is expected in Q4 2026. Existing cash and cash equivalents, combined with the upfront proceeds from the Trinity debt facility, are projected to fund operations into Q1 2027.

Management Comments

• "This quarter we continued to make strong progress across our clinical pipeline."
• "We continue to work toward a planned BLA submission in Q4 2026."
• "On the financial front, we were pleased to secure strategic, non-dilutive funding through a five-year, $130 million term loan facility with Trinity Capital, Inc., which strengthens our balance sheet and positions us to advance our key priorities, including the initiation of a pivotal phase 3 clinical trial of CAN-2409 in NSCLC and the potential commercial launch of CAN-2409 in localized prostate cancer."

Industry Context

Candel Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on developing multimodal biological immunotherapies for cancer. The advancement of lead candidates CAN-2409 and CAN-3110 into pivotal trials and BLA preparation addresses significant unmet medical needs in difficult-to-treat cancers like prostate cancer, NSCLC, and high-grade glioma. The company's strategy of securing non-dilutive funding and leveraging FDA designations (Fast Track, RMAT, Orphan Drug) aligns with industry trends for biotech companies seeking to de-risk their pipelines, accelerate development, and extend financial runways amidst high R&D costs.

Comparison to Industry Standards

• The reported median overall survival (mOS) of 11.8 months (Arm A) and 12.0 months (Arm B) for CAN-3110 in recurrent high-grade glioma (rHGG) is noted as an improvement compared to historical controls, which is significant given the aggressive nature and poor prognosis of glioblastoma, a condition with limited effective therapies.
• The statistically significant improvement in prostate cancer-specific DFS (HR 0.62; p=0.0046) for CAN-2409 in localized prostate cancer represents a strong clinical outcome, positioning it favorably against existing or developing therapies for intermediate-to-high-risk localized prostate cancer, although specific competitor trial results are not detailed in the filing.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact due to strong clinical data, extended cash runway, and clear progress towards BLA submission and pivotal trials, which could drive future value. Dilution risk is mitigated by non-dilutive debt financing.
• Patients: Positive impact from the continued development of potential new immunotherapies for difficult-to-treat cancers like prostate cancer, NSCLC, and high-grade glioma, offering new treatment options.
• Employees: Continued employment and potential growth opportunities as clinical programs advance and the company expands its operations.
• Creditors (Trinity Capital Inc.): The new debt facility provides a return opportunity for Trinity Capital Inc. based on the terms of the loan agreement.

Next Steps

• Host a Virtual R&D Day on December 5, 2025.
• Expect updated mOS data and long tail of survival analysis from the phase 2a open-label clinical trial of CAN-2409 in NSCLC in Q1 2026.
• Expect updated data on prostate cancer-specific DFS, time to salvage anti-cancer therapy, and time to metastasis from the phase 3 clinical trial of CAN-2409 in localized prostate cancer after extended follow-up in Q2 2026.
• Plan to initiate a pivotal phase 3 clinical trial of CAN-2409 in NSCLC in Q2 2026.
• Expect data on local and systemic biomarkers of immune activation from a mechanistic, supportive clinical trial of CAN-2409 in localized prostate cancer in Q3 2026.
• Expect to present mature mOS data and an update on long-term survivors from arm C of the phase 1b clinical trial of CAN-3110 in recurrent glioblastoma in Q4 2026.
• Expect submission of a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.

Key Dates

Recommendation

The company reported highly encouraging clinical data for its lead candidate CAN-2409 in prostate cancer, demonstrating statistically significant disease-free survival improvement, which is a critical step towards regulatory approval. The plan to submit a BLA in Q4 2026 for this indication, coupled with the initiation of a pivotal Phase 3 trial for CAN-2409 in NSCLC, signals robust pipeline progression. Furthermore, the updated survival data for CAN-3110 in recurrent high-grade glioma is promising for a challenging disease. Financially, securing a $130 million non-dilutive term loan facility significantly strengthens the balance sheet and extends the cash runway into Q1 2027, mitigating near-term financing risks and providing capital for key development milestones. These factors collectively indicate strong operational execution and significant potential for future value creation, making it a compelling investment opportunity.

Keywords

Candel Therapeutics, CADL, biopharmaceutical, immunotherapy, cancer, oncology, CAN-2409, aglatimagene besadenovec, prostate cancer, non-small cell lung cancer, NSCLC, CAN-3110, linoserpaturev, high-grade glioma, glioblastoma, clinical trials, phase 3, BLA, FDA, Fast Track, RMAT, Orphan Drug, term loan, Trinity Capital, financial results, Q3 2025